By
Latest Stories
Don’t miss our hot and upcoming stories
Can MIT and Recursion’s New AI Model Boltz-2 Slash Drug Discovery Time by 1000x and Outperform AlphaFold3?
Key Takeaways• Boltz-2 delivers AI-driven binding affinity predictions 1000x faster than traditional free energy methods—dramatically…
Is Optic and Mechanica’s AI Venture Model the Future of Biotech Creation? Strategic Expansion Unifies Drug Discovery and Business Insight at Scale
Key Highlights Strategic Collaboration to Power AI-Led Biotech GrowthOptic, Inc., a pioneer in AI platforms…
Is the OBI Pharma–TegMine Therapeutics ADC Deal the Next Leap in Precision Oncology Using Glycan-Based Technologies?
Key Highlights 1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™The collaboration between…
Can AI Reveal the Hidden Biology of Cancer? Aitia and Gustave Roussy Join Forces to Decode Disease Causality for Next-Gen Therapies
Key Highlights: AI Collaboration to Decode Cancer ComplexityIn a bold step to redefine cancer treatment,…